155 related articles for article (PubMed ID: 11520790)
1. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.
Christophe OD; Lenting PJ; Cherel G; Boon-Spijker M; Lavergne JM; Boertjes R; Briquel ME; de Goede-Bolder A; Goudemand J; Gaillard S; d'Oiron R; Meyer D; Mertens K
Blood; 2001 Sep; 98(5):1416-23. PubMed ID: 11520790
[TBL] [Abstract][Full Text] [Related]
2. Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa.
Larson PJ; Stanfield-Oakley SA; VanDusen WJ; Kasper CK; Smith KJ; Monroe DM; High KA
J Biol Chem; 1996 Feb; 271(7):3869-76. PubMed ID: 8632006
[TBL] [Abstract][Full Text] [Related]
3. The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody.
Persson KE; Villoutreix BO; Thämlitz AM; Knobe KE; Stenflo J
J Biol Chem; 2002 Sep; 277(38):35616-24. PubMed ID: 12105230
[TBL] [Abstract][Full Text] [Related]
4. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
Boylan B; Rice AS; Neff AT; Manco-Johnson MJ; Kempton CL; Miller CH;
J Thromb Haemost; 2016 Oct; 14(10):1931-1940. PubMed ID: 27501440
[TBL] [Abstract][Full Text] [Related]
5. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.
Lenting PJ; Christophe OD; Maat H; Rees DJ; Mertens K
J Biol Chem; 1996 Oct; 271(41):25332-7. PubMed ID: 8810297
[TBL] [Abstract][Full Text] [Related]
6. Discontinuous residues of factor IX constitute a surface for binding the anti-factor IX monoclonal antibody A-5.
Chang YJ; Wu HL; Hsu YC; Hamaguchi N; Shi GY; Shen MC; Lin SW
Thromb Res; 2003; 111(4-5):293-9. PubMed ID: 14693178
[TBL] [Abstract][Full Text] [Related]
7. Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human factor IX.
Cheung WF; Stafford DW; Sugo T
Thromb Res; 1996 Jan; 81(1):65-73. PubMed ID: 8747521
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody.
Huang M; Furie BC; Furie B
J Biol Chem; 2004 Apr; 279(14):14338-46. PubMed ID: 14722079
[TBL] [Abstract][Full Text] [Related]
9. The factor VIIIa C2 domain (residues 2228-2240) interacts with the factor IXa Gla domain in the factor Xase complex.
Soeda T; Nogami K; Nishiya K; Takeyama M; Ogiwara K; Sakata Y; Yoshioka A; Shima M
J Biol Chem; 2009 Feb; 284(6):3379-88. PubMed ID: 19047063
[TBL] [Abstract][Full Text] [Related]
10. Epitope mapping of human factor IX inhibitor antibodies.
Takahashi I; Mizumo S; Kamiya T; Takamatsu J; Saito H
Br J Haematol; 1994 Sep; 88(1):166-73. PubMed ID: 7528527
[TBL] [Abstract][Full Text] [Related]
11. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII.
van den Brink EN; Turenhout EA; Bovenschen N; Heijnen BG; Mertens K; Peters M; Voorberg J
Blood; 2001 Feb; 97(4):966-72. PubMed ID: 11159524
[TBL] [Abstract][Full Text] [Related]
12. Alloantibodies in hemophilia B binding to multiple factor IX epitopes.
Thompson AR
Thromb Res; 1987 Apr; 46(1):169-74. PubMed ID: 2438804
[No Abstract] [Full Text] [Related]
13. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates.
Sawamoto Y; Shima M; Yamamoto M; Kamisue S; Nakai H; Tanaka I; Hayashi K; Giddings JC; Yoshioka A
Thromb Res; 1996 Aug; 83(4):279-86. PubMed ID: 8870172
[TBL] [Abstract][Full Text] [Related]
14. Construction, expression, and characterization of a chimera of factor IX and factor X. The role of the second epidermal growth factor domain and serine protease domain in factor Va binding.
Hertzberg MS; Ben-Tal O; Furie B; Furie BC
J Biol Chem; 1992 Jul; 267(21):14759-66. PubMed ID: 1634519
[TBL] [Abstract][Full Text] [Related]
15. Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.
Nishimura H; Takeya H; Miyata T; Suehiro K; Okamura T; Niho Y; Iwanaga S
J Biol Chem; 1993 Nov; 268(32):24041-6. PubMed ID: 8226948
[TBL] [Abstract][Full Text] [Related]
16. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex.
Ahmad SS; Wong MY; Rawala R; Jameson BA; Walsh PN
Biochemistry; 1998 Feb; 37(6):1671-9. PubMed ID: 9484238
[TBL] [Abstract][Full Text] [Related]
17. Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.
Levin D; Lagassé HA; Burch E; Strome S; Tan S; Jiang H; Sauna ZE; Golding B
J Thromb Haemost; 2017 Apr; 15(4):721-734. PubMed ID: 28166609
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
19. Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity.
Celie PH; Lenting PJ; Mertens K
J Biol Chem; 2000 Jan; 275(1):229-34. PubMed ID: 10617609
[TBL] [Abstract][Full Text] [Related]
20. The connecting segment between both epidermal growth factor-like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 domain.
Celie PH; Van Stempvoort G; Fribourg C; Schurgers LJ; Lenting PJ; Mertens K
J Biol Chem; 2002 Jun; 277(23):20214-20. PubMed ID: 11925427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
